The ACCC will face a test of its ability to win misuse of market power cases when a long-awaited judgment is handed down this week in the regulator’s appeal of a ruling dismissing its case alleging Pfizer misused its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
Viterra has failed in its third bid to access communications between Cargill Australia and its lawyers related to Cargill’s $420 million purchase of malt producer Joe White Maltings from Viterra in 2013.
A two-day hearing has been scheduled in the Westpac life insurance class action over a proposed funding arrangement that would give litigation backer JustKapital 30 per cent of any recovery, in addition to costs outlaid by lawyers for the class.
Taronga Conservation Society Australia and Sydney Zoo have agreed to settle their legal battle over the use of the name “Sydney Zoo”.
A Federal Court judge has given the all-clear to a $132.5 million offer by QBE to settle a class action by shareholders angry about a $5 billion stock market wipeout for the insurance provider.
A dispute with litigation funder Martin Place Litigation Services has cast doubt over whether Bannister Law can continue to lead a massive class action against Ford, the Federal Court heard Tuesday.
The former CEO of the lead contractor on the Snowy Hydro 2.0 project now facing corruption charges was the target of Australian Federal Police search warrants that were “too broad” to be sufficient, the Federal Court was told on Friday.
The Federal Court has ruled that the Ford Motor Company of Australia engaged in unconscionable conduct towards customers complaining about their troubled PowerShift transmission systems, and ordered the company to pay $10 million in penalties.
A Federal Court judge has criticised the lack of progress in a major class action brought against Ford Australia, telling the applicant’s barrister to “get his act together”.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.